1 Min Read
Feb 27 (Reuters) - Recro Pharma Inc
* Recro Pharma completes enrollment in Phase III safety study of IV Meloxicam Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.